3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Withdrawn
1
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gynecologic
1
Conditions
Breast Neoplasms
5
Neoplasms
4
Neoplasm Metastasis
4
Multiple Myeloma
3
Lymphoma
3
Leukemia
3
Hematologic Neoplasms
3
Triple Negative Breast Neoplasms
2
Prostatic Neoplasms
2
Ovarian Neoplasms
2
Glioblastoma
2
Fallopian Tube Neoplasms
2
Urinary Bladder Neoplasms
1
Recurrence
1
Rectal Neoplasms
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Malignant Female Reproductive System Neoplasm
1
Localized Head and Neck Carcinoma
1
Leukemia, Myeloid, Acute
1
Hematopoietic and Lymphoid System Neoplasm
1
Gastrointestinal Neoplasms
1
Fatigue
1
Endometrial Neoplasms
1
Depression
1
Colonic Neoplasms
1
Chemotherapy Effect
1
Caregiver Burden
1
Carcinoma, Ovarian Epithelial
1
Carcinoma, Non-Small-Cell Lung
1
Anxiety Disorders
1
Interventions
Paclitaxel
10
Carboplatin
6
Bevacizumab
5
pembrolizumab
4
Cyclophosphamide
4
olaparib
3
liposomal doxorubicin
3
fludarabine
3
ribociclib
2
palbociclib
2
mirvetuximab soravtansine
2
Topotecan
2
Nivolumab
2
Letrozole
2
Fulvestrant
2
Blood Specimen Collection
2
trastuzumab deruxtecan
1
sacituzumab govitecan
1
pegfilgrastim
1
niraparib
1
lenvatinib
1
isoquercitrin
1
fludarabine phosphate
1
durvalumab
1
cemiplimab
1
abemaciclib
1
Tinzaparin
1
Surveys and Questionnaires
1
Surgical Procedures, Operative
1
SLC25A33 protein, human
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recruiting
×
Carcinoma, Ovarian Epithelial
×
Palliative Care
×
Clear all
NCT07617753
2026-06-01
DUAL-OV-CAR-NK
Beijing Biotech
Phase 1/2
Recruiting
36 enrolled